2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - 260-262
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Study Population, Human
PAPER

824 Venetoclax, ixazomib, and dexamethasone for relapsed/refractory AL amyloidosis: Results of the Phase 1/1a multicenter VIDA study

Michael Rosenzweig, MD, Amandeep Godara, MD2, Craig Hofmeister, MD, MPH3, Carol Ann Huff4, Naresh Bumma, MD5, Kathleen Dorritie, MD6, Aaron S Rosenberg, MD7, Samuel Rubinstein, MD MSCI8, Arnab Chowdhury, MS9, James Sanchez, PhD10, Rabih Said11, Steven Gore, MD12, Alexey V. Danilov, MD, PhD13, Vaishali Sanchorawala, MD14
1 City of Hope, Duarte, California, United States
2 Huntsman Cancer Institute, University of Utah, Salt Lake City, California, United States
3 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
4 Johns Hopkins University, Baltimore, Maryland, United States
5 The Ohio State University Wexner Medical Center, Columbus, United States
6 UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
7 UC Davis Comprehensive Cancer Center, Davis, California, United States
8 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 AstraZeneca, Cambridge, United Kingdom
12 National Cancer Institute, Bethesda, Maryland, United States
13 City of Hope, Duarte, California, United States
14 Amyloidosis Center, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States

Background

Patients with relapsed/refractory systemic light chain amyloidosis (AL) are in need of safe and effective treatments. Venetoclax, a BCL2 inhibitor, has shown efficacy in patients with t(11;14), present in ~50% of AL patients. The proteasome inhibitor ixazomib has demonstrated benefit in AL, with low risk of peripheral neuropathy. Furthermore, synergy between venetoclax, proteosome inhibitors, and corticosteroids is known.

Methods

This study was a multicenter, phase 1/1a trial of venetoclax, ixazomib, and dexamethasone for relapsed/refractory AL. Key eligibility were histologically confirmed, relapsed AL after at least one line of therapy and presence of t(11;14) by FISH. The dosing schedule included venetoclax 400mg daily and dexamethasone 20mg weekly at each dose level (DL) on a 28-day cycle, with escalation of ixazomib doses (days 1, 8, 15) using a BOIN design. DL1, DL2, and DL3 included 2.3mg, 3mg, and 4mg ixazomib, respectively. Anti-microbial prophylaxis and tumor lysis prophylaxis were recommended rather than mandated. The primary objective was to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the combination. Secondary objectives were hematologic response, organ response, and progression free survival (PFS).

Results

Eighteen patients (8 female, 10 male) were enrolled, including 15 in the dose-escalation/ de-escalation phase (3 at DL1, 3 at DL2, and 9 at DL3) and 3 in the DL3 expansion phase. The median age was 66 years (range, 48-82), and patients had received a median of 2 prior lines of therapy (range, 1-4). No dose-limiting toxicities (DLTs) were observed at DL1, DL2, or the first three-patient cohort at DL3. In the second DL3 cohort, one patient experienced grade 4 dehydration, constituting a DLT. Per the BOIN design, a third three-patient cohort was enrolled at DL3, in which one patient experienced grade 3 nausea and missed an ixazomib dose, resulting in a DLT. Overall, 2/9 had a DLT at DL3; based on the posterior DLT estimate (23%), which was closest to the prespecified target toxicity rate at MTD (25%), DL3 was established as the MTD/RP2D. In an expansion cohort of three patients at DL3, one patient had grade 3 nausea lasting >7 days. This DLT was not included in the MTD determination per study design. No patients died from treatment-related complications.

The ≥grade 3 toxicities at each DL (the expansion cohort included in DL3) were classified as hematologic (DL1: 3 gr1, 1 gr2, 1 gr3; DL2: 4 gr1, 3 gr2, 1 gr4; DL3: 4 gr1, 5 gr2, 4 gr3, 2 gr4), gastrointestinal (DL1 4 gr1, 3 gr2; DL2: 2 gr1, 1 gr2; DL3: 14 gr1, 4 gr2, 7 gr3), metabolic (DL1: 1 gr1, DL2: 2 gr1, 2 gr2; DL3: 13 gr1, 4 gr2, 4 gr3, 2 gr4), infections (DL1: none, DL2: 1 gr1, 4 gr2; DL3: 6 gr2), neuropathy (DL1: 1 gr1, DL2 and DL3: none), and other (DL1: 4 gr1, 3 gr2, 2 gr3; DL2: 10 gr1, 5 gr2; DL3: 21 gr1, 7 gr2, 10 gr3). The most common all-grade toxicities were gastrointestinal and metabolic. Two patients started subsequent treatment, due to progression and DLT, respectively.

The overall hematologic response rate was 94% (95%CI: 73-99), and the complete hematologic response rate was 67% (95%CI: 41-87). The median PFS was not reached, and the 2-year PFS was 92% (95%CI: 56-98). In total, the median time to first response was 28 days (range: 26-147), the median time to best response was 43 days (range: 26-273), and the median duration of best response was 217 days (range: 28-841). Seven patients had organ responses, including 4 cardiac, 1 hepatic, and 2 renal.

Conclusions

For patients with relapsed/refractory t(11;14)-positive AL amyloidosis, this all-oral regimen of venetoclax, ixazomib, and dexamethasone appears to be safe, highly active, and capable of producing deep and rapid hematologic responses with meaningful organ improvement. The RP2D is venetoclax 400 mg daily + dexamethasone 20 mg weekly + ixazomib 4 mg on days 1, 8, and 15. The efficacy signals are strong enough to justify further clinical development.

The clinical trial is supported by NCI grant UM1CA186717. The clinical trial (clinicaltrials.gov, NCT04847453) is sponsored by the National Cancer Institute, part of National Institutes of Health, and led by City of Hope and conducted by the NCI's Experimental Therapeutics Clinical Trials Network (ETCTN). Genentech, AbbVie, and Millennium Pharmaceuticals provided support through a Cooperative Research and Development Agreement with NCI.

Michael Rosenzweig, MD: Nexcella - Research Funding